(603439)"GUIZHOU SANLI PHARMACEUTICAL CO., LTD."Report for Q3 2026
Filed with SSE · Stock code 603439 · · 11 pages · Chinese
Summary by 6ix AI
The report confirms the accuracy and completeness of the financial information provided, with the board of directors taking legal responsibility for its contents. Key financial data includes revenue and profit figures, with specific attention to changes compared to the previous year. The report also outlines the company's total assets and shareholders' equity at the end of the reporting period.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
GuiZhou SanLi Pharmaceutical Co., Ltd. on 6ix
Earlier from GuiZhou SanLi Pharmaceutical
- (603439)"GUIZHOU SANLI PHARMACEUTICAL CO., LTD."Announcement on Release of Pledge and Pledge of Certain Shares Held by Controlling Shareholder
- Announcement on Abnormal Fluctuations in Stock Trading
- Semi-annual Report for 2026
- Announcement on Reply to the Shanghai Stock Exchange's Information Disclosure Supervisory Inquiry Letter on the Company's 2025 Annual Report
- Announcement on Implementation of Repurchase and Cancellation of Restricted Shares under the Equity Incentive Plan
Follow GuiZhou SanLi Pharmaceutical into a list and get an email when it puts out news.
Follow GuiZhou SanLi Pharmaceutical